Respiratory Cachexia Nutrition Market Intelligence: Size, Share and Growth Outlook Through 2036

Market Overview

Size, screening, and conversion

• Brevintel analysis values respiratory cachexia nutrition at USD 161.9 million in 2026 ($162M), rising to USD 362.8 million by 2036 ($363M) at an 8.4% CAGR.
• Demand is generated when respiratory teams identify low BMI or involuntary weight loss that ordinary meals cannot correct within tolerated intake, then repeat the same medical-nutrition regimen.
• A 2025 European Respiratory Society Congress study of 62 men with COPD found malnutrition concentrated in ABE group E, sharpening the case for screening in severe follow-up.
• That concentration makes nutrition review relevant during severe COPD visits, so intervention can start before further weight loss reduces remaining intake capacity.
• Commercial conversion still depends on patients entering diagnosed care early enough to receive a nutrition assessment and continue treatment after discharge at home.
• KDCA updated COPD guidance in June 2026 and estimated prevalence near 13% among South Korean adults aged 40 or older, a large clinical base relative to treated nutrition use.
• The same guidance reported diagnosis at 2.8% and treatment at 1.6% of patients with COPD, leaving most underlying disease outside sustained medical-nutrition pathways.
• The treatment gap therefore narrows the pool that can enter repeat respiratory cachexia nutrition despite a substantial undiagnosed and untreated disease burden.

Clinical entry points after diagnosis

• GOLD 2026 instructs clinicians to measure BMI at every visit and maintain adequate nutrition during COPD management, giving clinical nutrition a documented entry point.
• Advanced COPD is projected to account for 47.1% of condition demand in 2026 because visible weight loss and routine nutrition assessment are already part of respiratory review.
• Energy-dense low-volume oral nutritional supplements (ONS) are estimated to hold 49.5% of formulation demand in 2026, matching breathlessness and early satiety constraints.
• Ready-to-drink (RTD) formats are expected to represent 42.7% of product-form demand in 2026, removing mixing steps from routines that already include inhalers and daily therapies.
• Homecare is estimated to capture 49.8% of end-user demand in 2026, with hospitals and long-term care accounting for the remaining share after oral intake continues post-discharge.
• Hospital pharmacy is forecast to account for 47.3% of sales-channel demand in 2026 because formulary selection during inpatient care often sets the first product patients receive.
• NHS Hampshire and Isle of Wight stated in March 2026 that adult community ONS should provide an additional 600 to 1,000 kcal per day, making home continuity clinically material.
• Storage convenience and local supply then determine whether patients maintain the planned dose between respiratory follow-up visits rather than dropping the prescribed volume.

Market Dynamics

Drivers

• Earlier recognition of disease-related malnutrition supports use once low BMI or involuntary weight loss is documented inside respiratory clinics rather than treated as a general dietary issue.
• GOLD 2026 BMI measurement at every visit gives dietitians a scheduled reason to start energy-dense low-volume ONS before intake capacity declines further.
• The 2025 European Respiratory Society Congress finding in 62 men that malnutrition clustered in ABE group E supports screening during the most severe COPD follow-up window.
• Compact protein-focused formats improve daily tolerance when breathlessness and early satiety make standard supplement volumes unrealistic during repeated treatment.
• Meiji announced in March 2025 that its Meibalance Mini Cup soup series would expand with an onion soup flavor, extending ready-to-drink compact nutrition for low-volume use.
• RTD formats at 42.7% of 2026 product-form demand reduce preparation burden and keep serving volume consistent for patients who may not mix powders reliably at home.
• Homecare at 49.8% of 2026 end-user demand converts a hospital recommendation into a routine purchase once patients resume daily respiratory therapies after discharge.
• Hospital pharmacy at 47.3% of 2026 channel demand remains the first selection point during exacerbation admissions, when dietitians can assess weight loss before discharge.

Restraints, payment gaps, and formulation response

• Adherence and payment gaps still limit continuity even after a clinician identifies nutrition risk, especially where oral products sit outside funded enteral-nutrition benefits.
• In the USA, hospital and retail channels can start oral nutrition, but oral products sit outside Medicare enteral nutrition benefits, interrupting continuity after initiation.
• KDCA’s 13% prevalence estimate versus 2.8% diagnosis and 1.6% treatment in June 2026 guidance shows how few COPD patients reach sustained medical nutrition.
• KDCA reported in July 2026 that 94.5% of patients with COPD had at least one comorbidity, so urgent competing conditions can delay nutrition during the same visit.
• UK local formularies can narrow product access even where dietitians identify the same clinical need, forcing switches after acute care if discharge supply is unreliable.
• In Germany, statutory insurance can fund balanced enteral diets only if ordinary food and other measures cannot adequately correct intake, raising documentation burden.
• The G-BA approved an evaluation concept in June 2025 covering current provision of balanced enteral diets and rules that may need adjustment for medical-necessity claims.
• Taste, texture, and small-portion palatability can weaken Japanese repeat use even where nutrition need is clear, so compact cups and familiar formats remain decisive.

Segmentation Analysis

Formulation

• Formulation covers energy-dense low-volume ONS, omega-3 EPA-enriched blends, leucine-HMB anti-catabolic products, and other formulations used in respiratory cachexia care.
• By formulation, energy-dense low-volume ONS is estimated to hold 49.5% in 2026 owing to concentrated servings that reduce daily intake volume during breathlessness.
• Breathlessness and early satiety can make standard oral clinical nutrition volumes unrealistic, so smaller servings let dietitians raise calorie or protein delivery.
• Repeated use depends on patients finishing the prescribed volume during poor appetite or breathlessness without displacing ordinary meals during treatment.
• Omega-3 EPA-enriched blends and leucine-HMB anti-catabolic products address inflammation and muscle-loss pathways that sit alongside calorie density in cachexia care.
• Other formulations remain available where patients cannot tolerate the leading energy-dense low-volume ONS profiles or need an alternative macronutrient mix.
• Clinicians can link supplementation to weight history and intake records instead of treating nutrition loss outside respiratory management once BMI is tracked.
• GOLD 2026 BMI checks therefore give energy-dense low-volume ONS a clearer clinical entry than respiratory conditions with inconsistent nutrition screening.

Condition

• Condition includes advanced COPD (pink puffer phenotype), ILD and pulmonary fibrosis, bronchiectasis, and other respiratory conditions associated with nutrition risk.
• Advanced COPD is projected to account for 47.1% of condition demand in 2026 attributable to visible weight loss and routine nutrition assessment in respiratory clinics.
• Advanced COPD gives teams a defined reason to monitor nutritional decline because breathlessness and exacerbations can reduce intake between scheduled visits.
• GOLD 2026 BMI measurement at every visit makes COPD a more reliable screening setting than conditions where nutrition review is still ad hoc.
• ILD and pulmonary fibrosis add progressive breathlessness and reduced meal volume, supporting medical nutrition when ordinary food cannot close the calorie gap.
• Bronchiectasis and other respiratory conditions associated with nutrition risk contribute residual demand where infection burden and fatigue suppress intake.
• The 2025 study of 62 men with COPD showing malnutrition concentrated in ABE group E reinforces why severe COPD, not milder disease, anchors condition mix.
• Nutrition screening during severe COPD follow-up can start before further weight loss reduces intake capacity and closes the window for oral supplementation.

Product form

• Product form separates RTD and powders from puddings, semi-solids, and other formats used when patients cannot finish a conventional drinkable serving.
• RTD is expected to represent 42.7% of product-form demand in 2026 driven by immediate use and consistent serving volume without mixing or measurement.
• RTD formats remove preparation from routines that may already include inhalers and daily therapies, supporting adherence outside supervised care.
• Meiji announced in March 2025 that its Meibalance Mini Cup soup series would expand with an onion soup flavor, extending compact ready-to-drink options.
• Flavor variety can extend repeat consumption since patients do not need preparation before each nutrition occasion and can rotate palatable options.
• Powders remain relevant where cost, storage, or titration favors mixing, but preparation burden can reduce routine intake if caregivers are unavailable.
• Puddings and semi-solids serve patients who cannot tolerate drink volumes, providing another route to calories when satiety or swallow comfort is limited.
• Ready-to-use therapeutic nutrition becomes more relevant if preparation burden reduces intake outside supervised care and patients miss prescribed calories.

End user and sales channel

• End users include homecare, hospitals, and long-term care, while sales channels cover hospital pharmacy, retail pharmacy, online, and institutional tender routes.
• By end user, homecare is estimated to capture 49.8% in 2026, with hospitals and long-term care accounting for the remaining share as oral consumption continues after discharge.
• Homecare determines whether a hospital nutrition recommendation becomes a routine purchase once patients resume daily therapies in the community.
• NHS Hampshire and Isle of Wight stated in March 2026 that adult community ONS should provide an additional 600 to 1,000 kcal per day, so missed home access cuts intake immediately.
• Hospital pharmacy is forecast to account for 47.3% of sales-channel demand in 2026 owing to formulary selection during inpatient care and exacerbation admissions.
• Adjacent enteral nutrition pathways explain why institutional stock can determine which product patients first receive before a community switch is even considered.
• Retail pharmacy, online, and institutional tender routes support refill and contract supply once a formulary or discharge instruction has named the product.
• A formulary decision has greater value if discharge instructions preserve product continuity through hospitalization and the community transition that follows.

Regional Outlook

Country growth spread

• Country forecasts span 2.6 percentage points between South Korea at 8.9% and Japan at 6.3%, so rank order is less informative than diagnosis depth and funded continuity.
• South Korea and the USA form the upper pair, while the UK and Germany follow closely and Japan defines the lower boundary of the published country set.
• South Korea retains untreated COPD cases that leave nutrition need outside regular respiratory follow-up, even as the country posts the fastest listed CAGR at 8.9%.
• The USA offers retail availability while oral products sit outside Medicare enteral nutrition benefits, producing an 8.0% CAGR with interrupted continuity risk.
• The UK carries dietitian recommendations into community care through respiratory review and discharge pathways, supporting a 7.7% CAGR over the assessment period.
• German pharmacies support clinician-directed nutrition and reduce reliance on direct consumer product discovery, consistent with a 7.2% CAGR through 2036.
• Japan favors familiar small-cup nutrition formats that lower switching friction for established domestic brands, alongside a 6.3% CAGR by 2036.
• Comparable CAGRs still produce different revenue conditions across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

United States and United Kingdom

• Respiratory cachexia nutrition demand in the USA is forecast to rise at 8.0% CAGR over the forecast period owing to diagnosed COPD volume and mixed hospital-retail starts.
• NCHS reported in May 2025 that COPD affected 3.8% of adults in 2023 and 10.5% of adults aged 75 or older, creating more nutrition-review opportunities in geriatric care.
• Older patients create more nutrition-review opportunities while fragmented reimbursement can interrupt continuity after an oral product is recommended in the USA.
• Manufacturers need payer-specific evidence and geriatric care-service channels that preserve access after hospital or outpatient initiation in the USA.
• COPD prevalence varies materially among English local authorities and changes the number of patients reaching nutrition review in each service area.
• The Chief Medical Officer documented a roughly 0.5% to 3.8% local-authority prevalence range in September 2025 using 2024 data, underscoring geographic access differences.
• The UK respiratory cachexia nutrition outlook is anticipated to advance at 7.7% CAGR over the assessment period, supported by routine respiratory review structures.
• Manufacturers with clear formulary evidence and reliable discharge supply can preserve repeat use without forcing patients to switch products after acute care in the UK.

Germany, Japan, and South Korea

• Adoption of respiratory cachexia nutrition in Germany is estimated to expand at 7.2% CAGR through 2036 attributable to a defined prescription route for balanced enteral diets.
• Statutory insurance in Germany can fund balanced enteral diets if ordinary food and other measures cannot adequately correct nutritional intake, subject to medical necessity.
• The G-BA approved an evaluation concept in June 2025 covering current provision of balanced enteral diets and rules that may need adjustment, so evidence packs must fit criteria.
• Japan’s Statistics Bureau reported in September 2025 that 36.19 million people were aged 65 or older and represented 29.4% of the population, an aging base for compact nutrition.
• Respiratory cachexia nutrition sales in Japan are forecast to expand at 6.3% CAGR by 2036 driven by that aging patient base and familiar medical nutrition formats.
• Small portions and palatability carry unusual weight in Japan because older patients may need concentrated nutrition without increasing meal volume they can tolerate.
• KDCA reported in July 2026 that 94.5% of patients with COPD had at least one comorbidity in national research, giving clinicians a reason to review weight during ongoing care.
• South Korea is estimated to post 8.9% CAGR over the forecast period driven by a sizable clinical burden and wider chronic-disease management, if nutrition stays visible in clinic time.

Competitive Landscape

Structure and offer design

• Competition centers on compact, palatable medical nutrition that respiratory and dietetic teams can start in hospital and continue in homecare without raising serving volume.
• Abbott Laboratories fields pulmonary-oriented oral nutrition such as PULMOCARE alongside Ensure, giving clinicians a familiar hospital-to-home brand path.
• Nestlé Health Science and Nutricia (Danone) compete on disease-specific oral nutrition portfolios, dietitian education, and discharge continuity into community supply.
• Fresenius Kabi and B. Braun SE bring institutional enteral and clinical-nutrition infrastructure that can influence which oral SKU is stocked beside tube-feeding pathways.
• Meiji Co., Ltd. (Meiji Holdings) extends compact ready-to-drink cups, including the March 2025 Meibalance Mini Cup onion soup expansion for low-volume supplementation.
• Medtrition, Inc. and Megalabs USA, LLC participate as specialty suppliers of targeted oral nutrition used when health-system formularies need additional compact options.
• Share of voice is won less on headline branding than on finishing the prescribed 600 to 1,000 kcal community target, RTD convenience at 42.7%, and homecare refill at 49.8%.
• Evidence that fits GOLD 2026 BMI review, German prescription criteria, and UK formulary documentation is now as material as flavor range for keeping patients on the first product.

Integrated producers

• Abbott Laboratories (PULMOCARE / Ensure)
• Nestlé Health Science
• Nutricia (Danone)
• Fresenius Kabi
• Meiji Co., Ltd. (Meiji Holdings)
• B. Braun SE

Specialty suppliers

• Medtrition, Inc.
• Megalabs USA, LLC